FY2029 Earnings Forecast for VRDN Issued By Leerink Partnrs

Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) - Leerink Partnrs issued their FY2029 earnings per share (EPS) estimates for Viridian Therapeutics in a report released on Monday, January 27th. Leerink Partnrs analyst T. Smith anticipates that the company will post earnings of $3.00 per share for the year. The consensus estimate for Viridian Therapeutics' current full-year earnings is ($4.03) per share.

A number of other equities analysts also recently commented on VRDN. Royal Bank of Canada boosted their target price on shares of Viridian Therapeutics from $44.00 to $47.00 and gave the stock an "outperform" rating in a report on Tuesday, December 17th. Needham & Company LLC reiterated a "buy" rating and issued a $38.00 target price on shares of Viridian Therapeutics in a report on Tuesday, January 7th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $27.00 target price (down from $37.00) on shares of Viridian Therapeutics in a report on Thursday, December 19th. HC Wainwright reiterated a "buy" rating and issued a $34.00 target price on shares of Viridian Therapeutics in a report on Monday, December 16th. Finally, TD Cowen started coverage on shares of Viridian Therapeutics in a report on Monday, November 25th. They set a "buy" rating on the stock. Three analysts have rated the stock with a hold rating and nine have issued a buy rating to the company's stock. According to data from MarketBeat.com, Viridian Therapeutics currently has an average rating of "Moderate Buy" and a consensus price target of $35.70.

Viridian Therapeutics Stock Up 1.6 %

Viridian Therapeutics stock traded up $0.30 during trading hours on Tuesday, reaching $19.21. The stock had a trading volume of 935,874 shares, compared to its average volume of 1,279,457. The company has a market cap of $1.52 billion, a price-to-earnings ratio of -4.46 and a beta of 1.13. The company has a debt-to-equity ratio of 0.04, a current ratio of 18.55 and a quick ratio of 18.55. The business's 50 day moving average price is $19.43 and its 200-day moving average price is $19.39. Viridian Therapeutics has a 52 week low of $11.40 and a 52 week high of $27.20.

Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) earnings per share for the quarter, missing the consensus estimate of ($1.11) by ($0.04). The firm had revenue of $0.09 million during the quarter, compared to the consensus estimate of $0.08 million. Viridian Therapeutics had a negative net margin of 85,127.16% and a negative return on equity of 70.12%.

Institutional Investors Weigh In On Viridian Therapeutics

Large investors have recently bought and sold shares of the company. R Squared Ltd purchased a new stake in Viridian Therapeutics in the 4th quarter worth approximately $26,000. Moody Aldrich Partners LLC purchased a new stake in Viridian Therapeutics in the 4th quarter worth approximately $1,125,000. SG Americas Securities LLC boosted its position in Viridian Therapeutics by 89.1% in the 4th quarter. SG Americas Securities LLC now owns 31,085 shares of the company's stock worth $596,000 after purchasing an additional 14,644 shares in the last quarter. Hennion & Walsh Asset Management Inc. boosted its position in Viridian Therapeutics by 6.8% in the 4th quarter. Hennion & Walsh Asset Management Inc. now owns 210,899 shares of the company's stock worth $4,043,000 after purchasing an additional 13,498 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its position in Viridian Therapeutics by 218.5% in the 3rd quarter. JPMorgan Chase & Co. now owns 400,351 shares of the company's stock worth $9,108,000 after purchasing an additional 274,641 shares in the last quarter.

About Viridian Therapeutics

Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.